by Bioblast Editor | Jul 19, 2019 | Biosimilars updates
Both Amgen and Celltrion’s biosimilar trastuzumab products, Kanjiti® and Herzuma® respectively, were considered by Australia’s PBAC committee for PBS listing and A flagging (substitution). This follows the May 2019 PBAC recommendations for PBS listing of...
by Bioblast Editor | Dec 20, 2018 | Biosimilars updates
FDA approves TmAb biosimilar for the treatment of HER2-positive breast cancer. Herzuma® is the second TmAb biosimilar to be approved in the US. Celltrion is currently defending the biosimilar against Genentech, and while Genentech and Pfizer have reached a settlement,...
